Legal Consequences of Record-Keeping Violations Under the Drugs Act

Introduction

The Supreme Court of India recently addressed significant issues regarding the prosecution of pharmaceutical firms for violations of the Drugs and Cosmetics Act, 1940. In the case of M/s SBS Biotech & Others vs. State of Himachal Pradesh, the Court examined the legal implications of non-compliance with record-keeping requirements mandated by the Act and its associated rules. This judgment clarifies the legal framework surrounding the prosecution of drug manufacturers and the jurisdiction of courts in such matters.

Case Background

The appellants, M/s SBS Biotech, a partnership firm engaged in pharmaceutical manufacturing, faced prosecution for alleged violations of the Drugs and Cosmetics Act. The case stemmed from an inspection conducted by a Drug Inspector in July 2014, which revealed significant discrepancies in the firm's record-keeping practices. The firm was accused of failing to maintain the requisite records as per Schedule M and Schedule U of the Drugs and Cosmetics Rules, 1945. Following the inspection, the Drug Inspector seized various documents and drugs, leading to a complaint filed against the appellants in February 2017.

What The Lower Authorities Held

The High Court of Himachal Pradesh dismissed the appellants' petition seeking to quash the complaint, affirming the jurisdiction of the Special Judge to try the offences under the Drugs Act. The High Court ruled that the limitation period for filing the complaint was three years, as the offence under Section 27(d) of the Act carries a maximum punishment of two years. The appellants contended that the cognizance taken by the Magistrate was flawed due to the omission of Section 27(d) in the order, which they argued was not merely a clerical error.

The Court's Reasoning

The Supreme Court, while dismissing the appeal, upheld the findings of the High Court. The Court emphasized that the allegations against the appellants were serious, involving significant violations of record-keeping requirements. The Court noted that Section 18(a)(vi) of the Drugs Act prohibits the manufacture of drugs in contravention of the Act, while Section 18-B specifically addresses the maintenance of records and the furnishing of information. The Court clarified that violations of these provisions could lead to prosecution under Section 27(d), which prescribes penalties for contraventions of the Act.

Statutory Interpretation

The Court interpreted the relevant provisions of the Drugs and Cosmetics Act, particularly Sections 18, 18-B, and 27(d). It highlighted that Section 18(a)(vi) pertains to the prohibition of manufacturing drugs in violation of the Act, while Section 18-B mandates that licensed manufacturers maintain accurate records. The Court found that the allegations against the appellants fell squarely within the ambit of these provisions, justifying the prosecution under Section 27(d).

The Court also addressed the limitation period for filing complaints under the Act. It clarified that since the offence under Section 27(d) carries a punishment of up to two years, the applicable limitation period is three years as per Section 468 of the Code of Criminal Procedure, 1973. The Court concluded that the complaint was filed within the permissible time frame, thereby rejecting the appellants' argument regarding the bar of limitation.

Constitutional or Policy Context

While the judgment primarily focused on statutory interpretation, it also underscored the importance of compliance with regulatory frameworks in the pharmaceutical industry. The Court's ruling reinforces the need for strict adherence to record-keeping requirements, which are crucial for ensuring the safety and efficacy of drugs in the market. This decision serves as a reminder to pharmaceutical firms about the legal obligations they must fulfill to operate within the bounds of the law.

Why This Judgment Matters

This ruling is significant for legal practice as it clarifies the legal consequences of non-compliance with record-keeping requirements under the Drugs and Cosmetics Act. It establishes that violations can lead to serious legal repercussions, including prosecution and penalties. The judgment also affirms the jurisdiction of Special Courts in handling such cases, thereby streamlining the legal process for addressing violations in the pharmaceutical sector. Legal practitioners and pharmaceutical companies must take heed of this ruling to ensure compliance with regulatory requirements and avoid potential legal pitfalls.

Final Outcome

The Supreme Court dismissed the appeal filed by M/s SBS Biotech & Others, thereby upholding the High Court's decision to reject the quashing petition. The Court confirmed that the prosecution against the appellants would proceed based on the allegations of record-keeping violations under the Drugs and Cosmetics Act.

Case Details

• Case Title: M/s SBS Biotech & Others vs. State of Himachal Pradesh
• Citation: 2026 INSC 171
• Court: IN THE SUPREME COURT OF INDIA
• Bench: Justice Prashant Kumar Mishra, Justice Vipul M. Pancholi
• Date of Judgment: 2026-02-20